The present invention relates to
chemistry and
pharmacy and, in particular, to the production of novel molecular entities,
tricyclic and tetracyclic derivatives of
benzodiazepine, pyridodiazepine and pyrimidodiazepine type fused with 1,4-
dihydropyridine derivatives, having an effect on the central-nervous and vascular systems. Derivatives containing a
dihydropyridine ring are used, by means of reactions with compounds of the ortho-phenylenediamine, ortho-diaminopyridine and ortho-
diaminopyrimidine type, and also subsequent conversions to some thereof, to obtain
tricyclic and tetracyclic derivatives of general formula I-XII that contain a
diazepine or diazepinone
nucleus fused to a 1,4-
dihydropyridine nucleus, in which the A ring is a substituted or unsubstituted
benzene,
pyridine or
pyrimidine ring. These molecular entities exhibit GABAergica and modulating action in the case of
calcium channels which can be used in the treatment of cardiovascular, cerebrovascular, neurodegenerative, neuropsychiatric and neurological disorders.